HER2 positive breast cancer | sciencenewsnet.in

Breaking News

Rising hospital closures disproportionately affect disadvantaged communities

Scientists discover higher levels of CO2 increase survival of viruses in the air and transmission risk

Recovering phosphorus from sewage sludge ash

Genetic hope in fight against devastating wheat disease

CHLA Physician-Scientist Hosts Event Inviting Families to Dispose of Unwanted Medications

These jacks-of-all-trades are masters, too: Yeast study helps answer age-old biology question

Living with Stage 3 lung cancer in your 80s and 90s

ETRI published Key International Standards for Wearable Healthcare

Study Unveils Balance of AI and Preserving Humanity in Health Care

Press Registration for the ASRS 2024 Annual Scientific Meeting Now Open

26 Apr, 2024

ESMO: HER2-targeting antibody-drug improves progression-free survival for women with deadly form of advanced breast cancer

September 18, 2021 sarah JonasResearch Results

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that treating women with HER2 positive metastatic breast cancer with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly prolongs the length of time the disease is controlled and cancer growth is halted when compared to the current standard of care, trastuzumab emtansine (T-DM1).